16.2
改良释药剂型旨在解决生物半衰期较短药物的局限性。这类剂型可在较长时间内维持稳定的治疗药物浓度,从而减少给药频率。稳定的药物水平有助于最大限度减少峰谷波动,从而降低不良反应、减少耐药风险,并提高整体治疗效果。
一种常见的改良释药剂型是延释制剂 ER。ER 具有多方面的临床和实用优势。它们可减少每日给药…
缓释制剂可通过减少给药频率并维持稳定的治疗药物浓度,帮助解决半衰期较短的药物所面临的挑战。
稳定的药物浓度可减少副作用,降低药物耐药性的风险,并改善治疗效果。
例如,缓释或ER制剂通过减少给药频率、维持治疗效果并提高耐受性,从而增强患者的依从性。
尽管这些制剂具有上述优点,但缓释制剂仍存在若干局限性。
存在缺陷的制剂设计可能导致剂量倾泻,从而引起药物过量释放,造成毒性反应。
大剂量药物在缓释剂型中可能面临体积限制,导致更难吞服。
此外,首过代谢可能因药物的代谢途径和剂型设计不同而对药物生物利用度产生不同程度的影响。肠溶包衣不当可能导致刺激或药物吸收不完全。
然而,缓释制剂对于提高药物疗效、安全性和治疗依从性仍然至关重要。
View the full transcript and gain access to JoVE Core videos
Q1: Why do modified-release dosage forms reduce the need for frequent dosing?
Modified-release forms maintain stable therapeutic drug concentrations over extended periods, addressing limitations of drugs with short biological half-lives. By sustaining consistent drug levels, these formulations reduce peak-trough fluctuations, minimize adverse effects, lower drug resistance risk, and improve overall treatment effectiveness while decreasing the daily doses required.
Q2: How do extended-release formulations improve patient compliance?
Extended-release formulations reduce dosing frequency and ensure sustained therapeutic effects, which enhances patient compliance—especially in chronic therapy. By minimizing missed doses and maintaining tolerability, ER products lower long-term healthcare costs and improve treatment adherence in patients managing chronic conditions and improving outcomes.
Q3: What is dose-dumping and why is it a concern in extended-release formulations?
Dose-dumping occurs when a failure in the controlled-release mechanism causes sudden, excessive drug release, potentially leading to toxic plasma concentrations. This risk is severe with drugs having narrow therapeutic windows, as the sudden spike in drug levels can cause serious toxicity rather than the intended sustained therapeutic effect.
Q4: How do gastrointestinal factors affect extended-release drug performance?
Variations in pH, motility, and enzymatic activity in the gastrointestinal environment alter drug release and absorption from extended-release products. If enteric coatings are poorly designed or compromised, drugs may be released prematurely, causing gastrointestinal irritation or reduced bioavailability, affecting modified release drug delivery systems drug release characteristics.
Q5: What size limitations do extended-release formulations face?
For drugs requiring large doses, extended-release tablets or capsules may become too large for easy swallowing, impacting patient acceptance and compliance. This physical constraint is a significant limitation of ER formulations, particularly for patients with difficulty swallowing or those requiring high therapeutic doses.
Q6: How does first-pass metabolism affect extended-release drug bioavailability?
First-pass metabolism variably affects drug bioavailability depending on the drug's metabolic pathway and formulation design. Extended-release formulations must account for these metabolic factors to ensure predictable drug levels, as inadequate formulation design can result in inconsistent bioavailability and reduced therapeutic effectiveness.
Q7: What makes extended-release formulations essential despite their limitations?
When appropriately designed and administered, extended-release formulations optimize drug delivery by enhancing efficacy, safety, and adherence to prescribed regimens. They are indispensable in managing chronic conditions by maintaining stable therapeutic drug levels, reducing side effects, and improving long-term patient outcomes.